Matritech (NASDAQ - NMPS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Matritech (NASDAQ - NMPS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Damon Pham who wrote (449)	6/11/1997 11:40:00 AM
From: Jon Tara	of 849

Kaiser Permanente adopts NMP-22 test! The reason for the price rise today. A huge validation for Matritech. Kaiser has always been agressive at cutting costs, and this is one of the major advantages of NMP22. "The test has significant benefit over other bladder cancer tests because it detects cancer at a very early stage through a simple urine test. There are also substantial economic advantages for the Kaiser network because the NMP22 Test provides the urologist with predictive information which helps to identify patients who need aggressive management from those who need less, thus improving overall patient management."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next